Ikarian Capital, LLC Astria Therapeutics, Inc. Transaction History

Ikarian Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$6.99 - $16.69 $1.64 Million - $3.91 Million	-234,120 Reduced 62.46%	140,687 $1.98 Million
Q3 2023 Nov 14, 2023	SELL	$6.89 - $9.86 $1.41 Million - $2.02 Million	-204,583 Reduced 35.31%	374,807 $2.8 Million
Q2 2023 Aug 14, 2023	SELL	$8.33 - $13.72 $2.42 Million - $3.98 Million	-290,000 Reduced 33.36%	579,390 $4.83 Million
Q1 2023 May 15, 2023	BUY	$11.2 - $15.79 $2.18 Million - $3.07 Million	194,214 Added 28.76%	869,390 $11.6 Million
Q4 2022 Feb 14, 2023	SELL	$7.44 - $14.89 $180,524 - $361,290	-24,264 Reduced 3.47%	675,176 $10.1 Million
Q3 2022 Nov 14, 2022	BUY	$2.97 - $10.34 $318,731 - $1.11 Million	107,317 Added 18.12%	699,440 $6.32 Million
Q2 2022 Aug 12, 2022	BUY	$2.46 - $6.96 $1.23 Million - $3.48 Million	499,900 Added 542.06%	592,123 $1.78 Million
Q1 2022 May 13, 2022	BUY	$3.92 - $7.1 $18,200 - $32,965	4,643 Added 5.3%	92,223 $619,000
Q3 2021 Nov 15, 2021	BUY	$7.32 - $12.9 $641,085 - $1.13 Million	87,580 New	87,580 $775,000

107

48.6M

48K

9.3K

Ticker ATXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,178,000
Market Cap $145M
Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.